Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that CD20 + status confers therapeutic sensitivity to Rituximab in patients with Non-Hodgkin Lymphoma.
The Republic of Ireland's Health Service Executive (HSE) has approved rituximab (375 mg/m^2) (56 day) for reimbursement as a treatment option for the maintenance treatment of previously untreated follicular CD20 positive, B-cell Non Hodgkin Lymphoma patients responding to induction therapy.
This statement is based on a regulatory approval from the Health Service Executive:
Maintenance therapy for the treatment of previously untreated follicular CD20 positive, B-cell Non Hodgkin Lymphoma patients responding to induction therapy.